Digestive Diseases and Sciences

, Volume 57, Issue 6, pp 1465–1468 | Cite as

Abdominal Mass, Anemia, Diabetes Mellitus, and Necrolytic Migratory Erythema

  • Motaz Qadan
  • Brendan Visser
  • Jinah Kim
  • Reetesh Pai
  • George Triadafilopoulos
Stanford Multidisciplinary Seminars


  1. 1.
    Becker SW, Kahn D, Rothman S. Cutaneous manifestations of internal malignant tumors. Arch Dermatol Syph. 1942;45:1069.CrossRefGoogle Scholar
  2. 2.
    McGavran MH, Unger RH, Recant L, Polk HC, Kilo C, Levin ME. A glucagon-secreting alpha-cell carcinoma of the pancreas. N Engl J Med. 1966;274:1408–1413.PubMedCrossRefGoogle Scholar
  3. 3.
    Santacroce L, Griffing GT. Glucagonoma. E-medicine Medscape online reference 2011. http://emedicine.medscape.com/article/118899-overview.
  4. 4.
    Stacpoole PW. The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev. 1981;2:347–361.PubMedCrossRefGoogle Scholar
  5. 5.
    Guillausseau PJ, Guillausseau-Scholer C. Glucagonomas: Clinical Presentation, Diagnosis, and Advances in Management. Basel: Karger; 1995.Google Scholar
  6. 6.
    Yao JC, Eisner MP, Leary C, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol. 2007;14:3492–3500.PubMedCrossRefGoogle Scholar
  7. 7.
    Kindmark H, Sundin A, Granberg D, et al. Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years. Med Oncol. 2007;24:330–337.PubMedCrossRefGoogle Scholar
  8. 8.
    Norton JA, Barie PS, Bollinger RR, et al. Surgery: Basic Science and Clinical Evidence. 2nd edn. New York: Springer; 2008.Google Scholar
  9. 9.
    Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore). 1996;75:53–63.CrossRefGoogle Scholar
  10. 10.
    Rosch T, Lightdale CJ, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med. 1992;326:1721–1726.PubMedCrossRefGoogle Scholar
  11. 11.
    Norton JA, Harris EJ, Chen Y, et al. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg. 2011;146:724–732.PubMedCrossRefGoogle Scholar
  12. 12.
    Maton PN. Use of octreotide acetate for control of symptoms in patients with islet cell tumors. World J Surg. 1993;17:504–510.PubMedCrossRefGoogle Scholar
  13. 13.
    Wilkinson DS. Necrolytic migratory erythema with carcinoma of the pancreas. Trans St Johns Hosp Dermatol Soc. 1973;59:244–250.PubMedGoogle Scholar
  14. 14.
    van Beek AP, de Haas ER, van Vloten WA, Lips CJ, Roijers JF, Canninga-van Dijk MR. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol. 2004;151:531–537.PubMedCrossRefGoogle Scholar
  15. 15.
    Norton JA, Kahn CR, Schiebinger R, Gorschboth C, Brennan MF. Amino acid deficiency and the skin rash associated with glucagonoma. Ann Intern Med. 1979;91:213–215.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Motaz Qadan
    • 1
  • Brendan Visser
    • 1
  • Jinah Kim
    • 2
  • Reetesh Pai
    • 2
  • George Triadafilopoulos
    • 3
  1. 1.Department of SurgeryStanford University School of MedicineStanfordUSA
  2. 2.Department of PathologyStanford University School of MedicineStanfordUSA
  3. 3.Division of Gastroenterology and HepatologyStanford University School of MedicineStanfordUSA

Personalised recommendations